BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 186 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q3 2019. The put-call ratio across all filers is 0.14 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $14,901,000 | +118.9% | 203,817 | +1.9% | 0.41% | +45.6% |
| Q1 2020 | $6,806,000 | -37.5% | 200,000 | 0.0% | 0.28% | -18.3% |
| Q4 2019 | $10,888,000 | -24.0% | 200,000 | -41.8% | 0.34% | -39.8% |
| Q3 2019 | $14,331,000 | -4.7% | 343,500 | 0.0% | 0.57% | +5.0% |
| Q2 2019 | $15,042,000 | +12.4% | 343,500 | +32.1% | 0.54% | +5.4% |
| Q1 2019 | $13,382,000 | +39.2% | 260,000 | 0.0% | 0.52% | +13.7% |
| Q4 2018 | $9,615,000 | -1.5% | 260,000 | 0.0% | 0.45% | +28.6% |
| Q3 2018 | $9,763,000 | -37.9% | 260,000 | -34.6% | 0.35% | -41.6% |
| Q2 2018 | $15,709,000 | +87.6% | 397,500 | +22.3% | 0.60% | +69.2% |
| Q1 2018 | $8,372,000 | +27.2% | 325,000 | +33.2% | 0.36% | +19.4% |
| Q4 2017 | $6,583,000 | -27.8% | 244,000 | 0.0% | 0.30% | -29.0% |
| Q3 2017 | $9,121,000 | +18.8% | 244,000 | -20.5% | 0.42% | +8.5% |
| Q2 2017 | $7,675,000 | – | 307,000 | – | 0.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 2,111,111 | $144,294,000 | 54.16% |
| Knoll Capital Management, LLC | 856,844 | $58,565,000 | 38.16% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,123,271 | $145,126,000 | 21.73% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 860,261 | $58,799,000 | 6.01% |
| ARS Investment Partners, LLC | 561,442 | $38,375,000 | 4.46% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $12,057,000 | 3.19% |
| Eventide Asset Management | 2,015,000 | $137,725,000 | 2.04% |
| Avidity Partners Management LP | 1,049,800 | $71,754,000 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,089 | $3,424,000 | 1.87% |
| Nicholas Investment Partners, LP | 375,654 | $25,676,000 | 1.79% |